2238 Brody, Jonathan - Thomas Jefferson University - Thomas Jefferson University

Jonathan Brody, PhD

Contact Dr. Brody

1015 Walnut Street
Curtis 611A
Philadelphia, PA 19107

(215) 955-2693
(215) fax

Most Recent Peer-reviewed Publications

  1. Studying RNA-binding protein interactions with target mRNAs in eukaryotic cells: Native ribonucleoprotein immunoprecipitation (RIP) assays
  2. Upgrading gemcitabine with recycled kinase inhibitors
  3. Argonaute CLIP-Seq reveals miRNA targetome diversity across tissue types
  4. HuR posttranscriptionally regulates WEE1: Implications for the DNA damage response in pancreatic cancer cells
  5. Commentary : Fusing transcriptomics to progressive prostate cancer
  6. Targeting PARP-1 allosteric regulation offers therapeutic potential against cancer
  7. PARP inhibitors for chemoprevention - Letter
  8. dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: A dual-institutional follow-up with the RTOG 9704 trial
  9. Structural implications for selective targeting of PARPs
  10. Targeting cell cycle and hormone receptor pathways in cancer
  11. Mitoxantrone targets human ubiquitin-specific peptidase 11 (USP11) and is a potent inhibitor of pancreatic cancer cell survival
  12. HuR is a post-transcriptional regulator of core metabolic enzymes in pancreatic cancer
  13. Dormant cancer cells contribute to residual disease in a model of reversible pancreatic cancer
  14. Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer
  15. Dual roles of PARP-1 promote cancer growth and progression
  16. Pancreatic cancer and premalignant tumors: Molecular aspects
  17. Molecular-based and alternative therapies for pancreatic cancer: Looking "out of the box"
  18. HuR's post-transcriptional regulation of death receptor 5 in pancreatic cancer cells
  19. Epidermal growth factor receptor and insulinlike growth factor 1 receptor expression predict poor survival in pancreatic ductal adenocarcinoma
  20. A novel survival-based tissue microarray of pancreatic cancer validates muc1 and mesothelin as biomarkers